Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Management of Bladder Cancer
A Comprehensive Text With Clinical Scenarios
Konety, Chang
Editore
Springer
Anno
2015
Pagine
479
ISBN
9781493918805
150,00 €
- Authored by experts in their respective fields
- Provides a single, comprehensive reference source
- Useful resource for physicians
This book provides a single, comprehensive reference source that incorporates the epidemiology, natural history, and the latest genetic and molecular biological findings of bladder cancer. This book discusses the diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer and incorporates the new findings on markers for the diagnosis of bladder cancer. Risk stratified treatment of non-muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline-based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. This book covers the application of chemotherapy for muscle invasive and advanced disease. The evidence-based application of multimodality therapy is highlighted. Gaps in current knowledge and important areas for clinical research are highlighted.
Authored by experts in their respective fields, Management of Bladder Cancer: A Comprehensive Text with Clinical Scenarios serves as an easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.
Table of Contents
Part I General Concepts
1 Epidemiology and Natural History.............................................. 3
Edward Messing and Emil Scosyrev
2 Screening for Bladder Cancer...................................................... 17
Laura-Maria Krabbe, Robert S. Svatek, and Yair Lotan
3 Pathology and Staging: Histopathology
and Cytopathology......................................................................... 31
Amber Mackey, Farnaz Hasteh, and Donna E. Hansel
4 Pathology and Staging: Genetics and Molecular Biology.......... 45
Sean McAdams and Michael C. Risk
5 Imaging in Localized and Advanced Bladder Cancer................ 59
Timothy Kim, Joshua G. Griffin, Jeffrey M. Holzbeierlein,
and Wade J. Sexton
6 New Imaging Techniques in the Staging
of Urothelial Carcinoma of the Bladder...................................... 73
Ramdev Konijeti and Adam S. Kibel
7 Socioeconomic Issues and Improved Quality of Care................ 85
John L. Gore
8 Quality of Life Measures............................................................... 95
Christopher B. Anderson, David F. Penson,
and Daniel A. Barocas
9 Prognostication and Risk Assessment.......................................... 111
Luis A. Kluth, Bernard H. Bochner, and Shahrokh F. Shariat
10 Clinical Trials and Emerging Therapeutic
Strategies in Bladder Cancer........................................................ 145
Richard M. Bambury, Robert B. Sims,
and Jonathan E. Rosenberg
Part II Non Muscle Invasive Bladder Cancer
11 Improved Diagnostic Techniques.................................................. 155
Seth P. Lerner and Alvin C. Goh
12 Clinical Scenario: Microscopic Hematuria
and Atypical Cytology................................................................... 171
Christopher S. Gomez, Mark S. Soloway, Jorge Raul Caso,
Claudia P. Rojas, and Merce Jorda
13 Localized Surgical Therapy and Surveillance............................. 179
Manish I. Patel and Paul D. Sved
14 Clinical Scenario: Initial High-Grade
Ta Tumor........................ 191
José L. Domínguez-Escrig and Eduardo Solsona Narbón
15 Clinical Scenario: Recurrent Ta Tumor....................................... 201
Joseph A. Gillespie and Michael A. O’Donnell
16 Clinical Scenario: Rapidly Growing, High Volume,
Low-Grade Ta Tumor.................................................................... 209
James S. Rosoff and Thomas E. Keane
17 Clinical Scenario: Low-Grade T1 Tumor.................................... 215
J. Alfred Witjes and Florine W.M. Schlatmann
18 Intravesical Therapy...................................................................... 223
Jennifer J. Ahn and James M. McKiernan
19 Clinical Scenario: Initial CIS........................................................ 239
Sima P. Porten and Colin P. Dinney
20 Management of BCG Recurrent Bladder Cancer...................... 245
Tracy M. Downs, Daniel J. Lee, and Douglas S. Scherr
21 Clinical Scenario: Persistent CIS and High-Grade
Ta Bladder Cancer After BCG..................................................... 265
Maurizio Brausi
22 Clinical Scenario: Management of Side Effects from Bacillus
Calmette-Guérin Bladder Instillation.......................................... 271
Donald L. Lamm and Nilay M. Gandhi
23 Guideline-Based Management of Non-muscle
Invasive Bladder Cancer: Comparison of the AUA,
EAU, ICUD, and NCCN Guidelines............................................. 277
Jeffrey C. Bassett, John D. Seigne, and Peter E. Clark
Part III Muscle Invasive Bladder Cancer
24 Open Radical Cystectomy............................................................. 293
J. Joy Lee, Dipen J. Parekh, and Mark L. Gonzalgo
25 Robotic Cystectomy....................................................................... 309
Michael Woods, Raj S. Pruthi, and Erik P. Castle
26 Clinical Scenario: T2 Bladder Tumor.......................................... 327
Richard E. Hautmann
27 Urinary Diversion: Open and Robotic Techniques..................... 337
Norm D. Smith, Gary D. Steinberg, and Cheryl T. Lee
28 Chemoradiotherapy....................................................................... 361
Christian Weiss and Claus Rödel
29 Clinical Scenario: Bladder Preservation...................................... 379
Albert J. Chang, Maurice Marcel Garcia, and Mack Roach III
30 Management of Bladder Cancer, Role of Chemotherapy
and Controversies Surrounding Its Application......................... 387
Gautam Jha, Guru Sonpavde, and Zeeshan Ahmad
31 Clinical Scenario: Large Volume, Non-metastatic
T2 Bladder Tumor......................................................................... 405
Chad R. Ritch and Michael S. Cookson
32 The Role of Pelvic Lymphadenectomy
at the Time of Radical Cystectomy for Bladder Cancer............ 411
Samuel D. Kaffenberger, Todd M. Morgan,
and Anne K. Schuckman
33 Clinical Scenario: Unexpected Positive Nodes
at Radical Cystectomy................................................................... 423
Christian Thomas and Joachim W. Thüroff
34 Surveillance and Monitoring........................................................ 429
Daniel J. Canter, Joseph Zabell, Stephen A. Boorjian,
and Christopher J. Weight
35 Clinical Scenario: The Role of Perioperative
Chemotherapy................................................................................ 441
Eila C. Skinner
36 Clinical Scenario: Clinical Pelvic Nodal Metastases
After Complete Response to Chemotherapy............................... 449
Adam C. Reese and Mark Schoenberg
37 Guideline-Based Management of Muscle-Invasive
Bladder Cancer: NCCN, ICUD, and EAU.................................. 457
Amanda N. Calhoun and Kamal S. Pohar
Index........................................................................................................ 465
